Pharmacological Treatments for Melanoma
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 June 2024 | Viewed by 10243
Special Issue Editors
Interests: nitric oxide; endothelium; melanoma biology; angiogenesis; vascular inflammation; cardiovascular disease
Special Issues, Collections and Topics in MDPI journals
Interests: acidic-adapted melanoma cells; tumor microenvironment
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cutaneous melanoma is one of the most invasive and metastatic human tumors and accounts for most skin cancer deaths despite comprising less than 5% of all cutaneous malignancies; it has an incidence that grows faster, in both males and females, compared to other malignancies. Treatment strategies for the advanced disease have dramatically changed in recent years, improving the life expectancy of melanoma patients by significantly increasing their overall survival (OS) and progression-free survival (PFS) due to the introduction of BRAF/MEK inhibitors and immunotherapy. However, many patients display resistance, both innate and acquired, to systemic treatments. For these reasons, a lot of studies have been made to understand the molecular mechanisms of de novo and acquired resistance to targeted therapies to eventually treat patients who progress on these treatments.
For this Special Issue, we welcome research articles and reviews that present the latest evidence on melanoma research and new possible therapeutic targets that can contribute to deepening the knowledge on this aggressive and complex tumor and, eventually, overcoming acquired resistance to BRAF/MEK inhibitors.
Dr. Astrid Parenti
Dr. Anna Laurenzana
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- advanced melanoma
- immune escape
- metastasis
- targeted therapies
- biomarkers
- precision medicine
- tumor microenvironment